The time-varying cardiovascular benefits of Glucagon like peptide-1 receptor agonist therapy in patients with type 2 Diabetes Mellitus: Evidence from large multinational trials.

The Time-varying Cardiovascular benefits of Glucagon like peptide-1 receptor agonist therapy in patients with type 2 Diabetes Mellitus: Evidence from large multinational trials – Diabetes, Obesity & Metabolism

Commentary: Survival time analysis shows CV benefits of GLP1 receptor agonists – medwireNews